Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03078010 · ClinicalTrials.gov registry record · Phase 2
Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant
A Phase 2 study of Febrile Neutropenia and Intestinal Microbiome, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 347
- Enrollment target
- 2
- Study locations
NCT03078010 is a Phase 2 study of Febrile Neutropenia and Intestinal Microbiome that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 347 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT03078010, a Phase 2 study of Febrile Neutropenia and Intestinal Microbiome, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 347 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to see how different antibiotics affect the community of friendly bacteria existing in the intestinal tract (gut). Under normal circumstances, these friendly bacteria are not harmful and they help with normal bodily functions such as digestion. When these bacteria are absent, several complications may occur, such as infections with harmful bacteria or other inflammatory reactions, that can complicate the stem cell transplant course. Treatment with antibiotics or chemotherapy is known to kill off these friendly bacteria. In this study we compare the effects of different antibiotics on the community of friendly bacteria in the gut. For microbiota-related biomarker analysis, optional urine samples (MSKCC patients only) will be collected at baseline, 7 +/-2 days after initiation of antibiotic therapy, and on post-transplant days +28, +56 and +100 (+/- 7days).
Conditions Studied
Interventions
- DRUG Piperacillin-tazobactam
- DRUG cefepime
Study Locations (2)
New Jersey
- Hackensack Meridian Health - Hackensack
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 347 participants |
| Start Date | 2017-02-10 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03078010
The ClinicalTrials.gov registry entry for NCT03078010 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 347 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Febrile Neutropenia appearing as the primary indexed condition, and to 2 interventions - of which Piperacillin-tazobactam is the first listed.
NCT03078010 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT03078010 about?
NCT03078010 is a clinical study titled "Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant". The purpose of this study is to see how different antibiotics affect the community of friendly bacteria existing in the intestinal tract (gut). Under normal circumstances, these friendly bacteria are not harmful and they help with normal bodily functions such as digestion. When these bacteria are ab...
What is the current status of trial NCT03078010?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 347 participants. The study started on 2017-02-10. Estimated completion is 2027-02.
What conditions does trial NCT03078010 study?
This clinical trial studies the following conditions: Febrile Neutropenia, Intestinal Microbiome.
What interventions are being tested in trial NCT03078010?
The interventions under investigation include: Piperacillin-tazobactam (DRUG), cefepime (DRUG).
Who is sponsoring clinical trial NCT03078010?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03078010 being conducted?
This trial has 2 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Febrile Neutropenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.